Mohamad E. Allaf, Md, On Non-Metastatic Renal Cell Cancer Patients And Adjuvant Therapy

Mohamad E. Allaf, MD, on non-metastatic renal cell cancer patients and adjuvant therapy

Mohamad E. Allaf, MD, on helping non-metastatic renal cell carcinoma patients with adjuvant therapy

Neoadjuvant/ Adjuvant Immunotherapy in Localized Renal Cell Carcinoma: The PROSPER Trial and Beyond

Grand Rounds in Urology

Mohamad E. Allaf, MD, on immunotherapies and renal cell carcinoma treatment algorithms

Mohamad E. Allaf, MD, shares the most intriguing research presented at ASCO GU 2017

Mohamad E. Allaf, MD, Johns Hopkins Medicine, Department of Urology

Johns Hopkins Urology

A Phase III Trial of Pembrolizumab as Adjuvant Treatment for Renal Cell Carcinoma

Targeted Oncology

Dr. Fakih on Anti-Angiogenesis Versus Anti-EGFR Therapy in Colon Cancer

Latest in adjuvant therapy for renal cell carcinoma

New Developments in Adjuvant Therapy for Renal Cell Carcinoma Scott S. Tykodi, M.D., Ph.D.

A New Era of the Brady

Johns Hopkins Urology

Community Partnership in Prostate Cancer

Johns Hopkins Urology

Eric Jonasch, MD, on targeted therapies used to treat non-clear cell renal cell carcinoma

David J. McConkey, PhD, on non-invasive imaging and monitoring metastatic bladder cancer

Systemic Therapy for Metastatic Non-clear Cell RCC: Are There Any Good Options?

The faces of Mitochondrial Disease

EA8143/PROSPER RCC Clinical Trial for Renal Cell Carcinoma

ECOG-ACRIN Cancer Research Group

Nazem Atassi and Merit Cudkowicz on Sanofi Himalya trial in ALS

Adjuvant Therapy for Locally Advanced Renal Cell Carcinoma: Status in 2018

David J. McConkey, PhD, on which drugs have the highest potential to impact bladder cancer treatment